Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content.

The pharmacogenomics journal - 1 Aug 2016

Shirasaka Y, Chaudhry A S, McDonald M, Prasad B, Wong T, Calamia J C, Fohner A, Thornton T A, Isoherranen N, Unadkat J D, Rettie A E, Schuetz E G, Thummel K E

Abstract excerpt

Large interindividual variability has been observed in the metabolism of CYP2C19 substrates in vivo. The study aimed to evaluate sources of this variability in CYP2C19 activity, focusing on CYP2C19 diplotypes and the cytochrome P450 oxidoreductase (POR). CYP2C19 gene analysis was carried out on 347 human liver samples. CYP2C19 activity assayed using human liver microsomes confirmed a significant a priori...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clopidogrel
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxylation

Share to Linear Models

Share to Mephenytoin

Share to Microsomes, Liver

Share to Pharmacogenomic Variants

Share to Ticlopidine

Source

Open in PubMed Open full text

Identifiers

PMID: 26323597
DOI: 10.1038/tpj.2015.58
PMCID: PMC4775436

Genes

CYP2C19
POR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content.PMID 26323597Read ↗

From genes to drugs: CYP2C19 and pharmacogenetics in clinical practiceSemantic proximity Read ↗

Substantiation of a clopidogrel metabolism-associated gene (CYP2C19) variation among healthy individuals.Semantic proximity Read ↗

CYP2C19 polymorphism in relation to the pharmacotherapy optimization of commonly used drugsSemantic proximity Read ↗

CYP2C19 genotype-phenotype correlation: current insights and unanswered questionsSemantic proximity Read ↗

Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism: A retrospective study.Semantic proximity Read ↗

Genetic variability of CYP2C19 in a Mexican population: contribution to the knowledge of the inheritance pattern of CYP2C19*17 to develop the ultrarapid metabolizer phenotype.Semantic proximity Read ↗

Genotype-phenotype analysis of CYP2C19 in healthy saudi individuals and its potential clinical implication in drug therapy.Semantic proximity Read ↗

Impact of Genetic Polymorphisms in CYP2C9 and CYP2C19 on the Pharmacokinetics of Clinically Used DrugsSemantic proximity Read ↗

In Vitro Functional Characterisation of Cytochrome P450 (CYP) 2C19 Allelic Variants CYP2C19*23 and CYP2C19*24.Semantic proximity Read ↗

Global distribution of CYP2C19 risk phenotypes affecting safety and effectiveness of medications.Semantic proximity Read ↗

Prevalence of CYP2C9 and CYP2C19 variants and the impact on clopidogrel efficacy in patients having CYPC19*2 variant.Semantic proximity Read ↗

The impact of CYP2C19 genotype on phenoconversion by concomitant medicationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.